ACUTAAS CHEMICALS LIMITED

BSE: ACUTAAS543349ISIN INE00FF01025

Healthcare
Pharmaceuticals
BSE 500

Share price

₹3,777.65-137.45 (-3.51%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

Splits and bonuses

25 Apr 2025 · Split 2:1 (₹10 → ₹5)

52W high: ₹4,040.00
52W low: ₹1,571.20
Off 52W high: -6.49%
1M return: +21.13%
3M return: +15.04%
6M return: +40.82%
1Y return: +106.30%
20D avg volume: 51,662
50 DMA: ₹3,322.08
200 DMA: ₹2,850.08

Key ratios Consolidated

Market cap: ₹30,928 Cr
Current price: ₹3,777.65
52W high / low: ₹4,040.00 / ₹1,571.20
Face value: ₹5.00
P/E: 70.51
P/B: 16.65
EPS (TTM): ₹53.58
Book value / share: ₹226.87
ROE: —
ROCE: 27.70%
Operating margin: —
Net margin: —
Debt / equity: 0.02
Net debt: ₹-189.06 Cr
Interest cover: 148.62
Dividend yield: 0.07%
Dividend / share (TTM): ₹2.50
Payout: 4.67%
Cash conversion cycle: 119.9 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	436.92	329.68	432.75	393.18	306.20	207.24	308.48	274.99	246.73	176.67	224.96	166.44
	5.10	1.80	11.11	4.70	9.84	15.94	5.78	1.67	8.44	1.04	1.34	3.49
	442.01	331.48	443.86	397.88	316.03	223.18	314.26	276.66	255.17	177.71	226.30	169.94
	274.65	227.57	260.06	253.21	219.85	165.10	231.43	213.32	205.13	157.76	188.77	146.24
	156.49	165.77	183.69	175.97	131.24	104.06	164.55	157.21	142.99	105.06	134.43	86.14
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	42.06	39.57	33.29	29.86	29.35	25.07	23.30	21.67	19.63	19.06	17.04	16.14
	1.02	1.14	1.19	0.86	0.58	0.64	0.60	0.69	0.50	4.43	2.07	2.54
	12.69	9.82	9.63	9.82	8.40	8.13	7.30	6.32	6.83	6.18	4.90	3.76
	53.45	38.28	51.51	43.50	46.07	34.37	37.74	36.84	38.62	25.77	29.75	28.79
	167.36	103.91	183.80	144.67	96.18	58.08	82.83	63.33	50.04	19.95	37.53	23.70
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.33	0.00
	167.36	103.91	183.80	144.67	96.18	58.08	82.83	63.33	50.04	19.95	37.20	23.70
	44.22	28.92	49.52	38.45	24.32	14.07	20.12	17.89	12.47	5.26	11.53	5.89
	123.14	74.99	134.28	106.22	71.86	44.01	62.72	45.45	37.57	14.69	25.68	17.81
	15.29	9.07	16.09	13.19	8.82	5.41	7.80	11.35	9.38	3.67	6.86	4.83
Key metrics
	181.07	114.87	194.62	155.35	105.16	66.85	90.73	70.34	57.37	30.56	44.17	30.00
	41.40%	34.80%	45.00%	39.50%	34.30%	32.30%	29.40%	25.60%	23.30%	17.30%	19.60%	18.00%
	28.20%	22.70%	31.00%	27.00%	23.50%	21.20%	20.30%	16.50%	15.20%	8.30%	11.40%	10.70%
	8.60%	—	10.60%	—	6.60%	—	6.20%	—	—	—	—	—
	42.70%	59.10%	40.30%	43.00%	24.10%	17.30%	37.10%	65.20%	—	—	—	—
	71.40%	70.40%	114.10%	133.70%	91.30%	199.60%	144.20%	155.20%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	1,593	1,339	1,007	717.48	616.74	520.13
	22.71	41.59	16.93	7.49	4.32	2.76
	1,615	1,381	1,024	724.97	621.05	522.90
	1,015	898.23	807.64	610.98	508.88	431.45
	681.92	594.96	569.81	440.17	345.85	282.33
	0.00	0.00	0.00	—	—	—
	144.78	117.57	83.66	63.11	48.84	41.37
	4.21	3.27	6.22	5.94	2.41	6.41
	41.96	35.99	26.62	16.05	12.34	10.08
	186.74	175.44	138.97	114.18	114.40	100.76
	599.74	482.73	216.16	113.98	112.17	91.45
	0.00	0.00	0.00	-32.08	0.00	0.00
	599.74	482.73	216.16	81.90	112.17	91.45
	161.11	126.36	55.75	33.19	28.88	19.50
	438.63	356.37	160.42	48.71	83.29	71.95
	53.64	43.51	19.81	11.67	22.86	21.03
Key metrics
	645.91	521.99	249.00	103.89	126.92	107.94
	40.56%	39.00%	24.70%	14.50%	20.60%	20.80%
	27.54%	26.60%	15.90%	6.80%	13.50%	13.80%
	—	27.70%	16.50%	—	—	—
	45.18%	33.00%	40.30%	16.30%	18.60%	—
	95.78%	122.10%	229.30%	-41.50%	15.80%	—
	—	-35.81	-76.30	—	—	—
	—	0.82	0.74	—	—	—
	—	0.02	0.01	—	—	—
	—	-189.06	-177.04	—	—	—
	—	119.9	113.9	—	—	—
Balance sheet
	—	1,984	1,549	—	—	—
	—	881.27	791.64	—	—	—
	—	215.55	185.22	—	—	—
	—	362.56	290.49	—	—	—
	—	231.32	179.94	—	—	—
	—	—	0.00	—	—	—
	—	633.32	505.31	—	—	—
	—	153.91	156.05	—	—	—
	—	230.81	202.25	—	—	—
	—	26.49	8.18	—	—	—
	—	26.49	8.18	—	—	—
	—	0.00	0.00	—	—	—
	—	1,711	1,320	—	—	—
Cash flow
	—	292.17	118.34	—	—	—
	—	-265.94	-223.94	—	—	—
	—	4.10	261.12	—	—	—
	—	327.98	194.64	—	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	433.05	322.41	421.77	390.86	305.19	205.97	304.16	270.94	243.59	171.14	219.94	161.70
	8.05	4.48	14.55	6.34	8.97	16.02	5.69	2.17	8.58	1.90	8.55	2.87
	441.09	326.89	436.32	397.20	314.16	221.99	309.86	273.11	252.17	173.03	228.49	164.57
	260.01	222.87	250.46	246.49	216.88	163.06	227.04	210.57	202.15	154.83	186.20	144.23
	155.04	163.97	183.27	176.02	130.03	103.18	163.21	157.33	141.66	104.64	133.15	85.43
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	39.51	37.40	31.33	26.97	28.64	24.40	22.61	20.92	18.96	18.46	16.36	15.54
	0.99	1.12	1.07	0.81	0.57	0.62	0.38	0.61	0.49	4.37	2.06	2.56
	9.31	9.02	8.83	9.02	7.72	7.46	6.56	5.67	6.20	5.62	4.36	3.50
	47.41	35.69	46.58	42.31	44.79	33.95	36.26	36.16	37.57	25.56	29.20	27.79
	181.08	104.02	185.86	150.71	97.28	58.93	82.81	62.54	50.02	18.20	42.29	20.34
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	181.08	104.02	185.86	150.71	97.28	58.93	82.81	62.54	50.02	18.20	42.29	20.34
	45.34	28.12	48.79	39.14	24.39	14.28	19.97	17.24	12.34	4.49	10.21	4.64
	135.74	75.90	137.07	111.57	72.89	44.65	62.85	45.30	37.68	13.72	32.08	15.70
	16.58	9.27	16.74	13.63	8.90	5.45	7.84	11.31	9.41	3.43	8.75	4.26
Key metrics
	191.38	114.16	195.76	160.54	105.57	67.01	89.75	68.82	56.71	28.19	48.71	26.40
	44.20%	35.40%	46.40%	41.10%	34.60%	32.50%	29.50%	25.40%	23.30%	16.50%	22.10%	16.30%
	31.30%	23.50%	32.50%	28.50%	23.90%	21.70%	20.70%	16.70%	15.50%	8.00%	14.60%	9.70%
	9.50%	—	10.90%	—	6.70%	—	6.20%	—	—	—	—	—
	41.90%	56.50%	38.70%	44.30%	25.30%	20.40%	38.30%	67.60%	—	—	—	—
	86.20%	70.00%	118.10%	146.30%	93.40%	225.40%	95.90%	188.50%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	1,568	1,324	989.84	687.58	616.73	520.13
	33.42	45.88	18.34	13.79	4.32	2.76
	1,602	1,370	1,008	701.37	621.05	522.90
	979.83	876.90	794.60	600.50	508.83	431.45
	678.30	592.50	566.84	434.96	345.85	282.33
	0.00	0.00	0.00	—	—	—
	135.21	111.35	80.95	60.92	48.84	41.37
	3.99	3.08	5.86	5.89	2.41	6.41
	36.18	33.03	24.05	14.69	12.34	10.08
	171.99	167.63	135.55	110.97	114.34	100.76
	621.67	492.77	213.58	100.86	112.22	91.45
	0.00	0.00	0.00	-31.75	—	—
	621.67	492.77	213.58	69.11	112.22	91.45
	161.39	126.60	54.03	25.43	28.88	19.50
	460.28	366.18	159.55	43.69	83.34	71.95
	56.22	44.73	19.91	11.91	22.87	21.03
Key metrics
	661.84	528.88	243.49	89.69	126.97	107.94
	42.21%	40.00%	24.60%	13.00%	20.60%	20.80%
	29.35%	27.70%	16.10%	6.40%	13.50%	13.80%
	—	29.00%	16.40%	—	—	—
	44.36%	33.70%	44.00%	11.50%	18.60%	—
	103.94%	129.50%	265.20%	-47.60%	15.80%	—
	—	109.89	-75.08	—	—	—
	—	0.83	0.73	—	—	—
	—	0.01	0.00	—	—	—
	—	-135.99	-178.26	—	—	—
	—	120.2	113.4	—	—	—
Balance sheet
	—	1,935	1,538	—	—	—
	—	808.96	771.31	—	—	—
	—	160.04	184.61	—	—	—
	—	360.18	289.21	—	—	—
	—	226.67	174.00	—	—	—
	—	50.70	0.00	—	—	—
	—	598.21	495.91	—	—	—
	—	150.84	155.54	—	—	—
	—	223.57	199.04	—	—	—
	—	24.05	6.35	—	—	—
	—	24.05	6.35	—	—	—
	—	0.00	0.00	—	—	—
	—	1,668	1,312	—	—	—
Cash flow
	—	305.37	115.93	—	—	—
	—	-333.61	-234.37	—	—	—
	—	3.68	273.56	—	—	—
	—	195.48	191.01	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +29.00%
Sales CAGR 5Y: —
Profit CAGR 3Y: +63.79%
Profit CAGR 5Y: —
Sales YoY (TTM): +44.36%
Profit YoY (TTM): +103.94%

Consolidated

Sales CAGR 3Y: +29.50%
Sales CAGR 5Y: —
Profit CAGR 3Y: +62.34%
Profit CAGR 5Y: —
Sales YoY (TTM): +45.18%
Profit YoY (TTM): +95.78%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 32.66%

Quarter	September 2026	June 2026
Promoter %	32.66%	32.66%

Holder	Type	Holding	Previous	Change
Nareshkumar Ramjibhai Patel	Promoter	17.69%	17.69%	0.00%
Vaghasia Chetankumar Chhaganlal	Promoter	14.97%	14.97%	0.00%
DHWANI GIRISHKUMAR CHOVATIA	Public	3.35%	3.35%	0.00%
GOVERNMENT PENSION FUND GLOBAL	Public	3.11%	3.54%	-0.43%
KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK NIFTY ALPHA 50 INDEX FUND	Public	2.86%	—	—
AXIS MAX LIFE INSURANCE LIMITED A/C NIFTY MOMENTUM QUALITY 50 FUND	Public	2.04%	—	—
SBI NIFTY SMALLCAP 250 INDEX FUND	Public	1.83%	—	—
MOTILAL OSWAL NIFTY SMALLCAP 250 INDEX FUND	Public	1.81%	—	—
VANAJA SUNDAR IYER	Public	1.33%	1.14%	+0.19%
Sanjaykumar Ramnikbhai Thummer HUF	Promoter Group	0.00%	0.00%	0.00%
Carbon Square	Promoter Group	0.00%	0.00%	0.00%
Minal Vipulbhai Rakholiya	Promoter Group	0.00%	0.00%	0.00%
Rahil Infrastructure LLP	Promoter Group	0.00%	0.00%	0.00%
Vijaybhai Gordhanbhai Dayani	Promoter Group	0.00%	0.00%	0.00%
Nairit Chetankumar Vaghasia	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,37,952	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,69,451	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,449	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,26,703	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,19,341	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,13,578	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,243	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,03,881	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	1,02,895	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	90,887	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,147	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	61,956	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Biocon Ltd.	58,897	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Abbott India Ltd. S	56,508	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Gland Pharma Limited	51,934	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	49,458	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
Emcure Pharmaceuticals Limited	42,498	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
GlaxoSmithkline Pharmaceuticals Ltd.	42,363	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,012	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	33,915	1,546.30	90.80	18.10%	—	—	+67.49%
Wockhardt Ltd	32,340	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
PIRAMAL PHARMA LIMITED	31,793	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,838	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
RUBICON RESEARCH LIMITED	28,809	1,716.55	98.59	24.30%	—	—	+164.06%

Filings & corporate actions

Recent announcements

Transcript for Earnings call for Q2 FY 2027 Financial Results held on October 27, 2026 is attached2 Nov 2026 · Company Update / Earnings Call Transcript
Intimation under Regulation 30 of SEBI (LODR) Regulation, 2015 is attached.2 Nov 2026 · Company Update / Change in Management
Newspaper Publication of the Unaudited Financial Results for the second quarter ended September 30, 2026 as attached.28 Oct 2026 · Company Update / Newspaper Publication
Recording to earnings call held on October 27, 2026 is attached.27 Oct 2026 · Company Update / Analyst / Investor Meet
Investor Presentation on financial results for the second quarter and half year ended as on September 30, 2026 is enclosed.27 Oct 2026 · Company Update / Investor Presentation
Press Release discussing the financial results for the second quarter and half year ended as on September 30, 2026 is attached.27 Oct 2026 · Company Update / Press Release / Media Release
Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026 is enclosed.27 Oct 2026 · Result / Financial Results
The Board of Directors of the Company at their meeting held on Friday, October 27, 2026, inter alia, considered & approved Unaudited Standalone & Consolidated Financial Results of the Company ....27 Oct 2026 · Board Meeting / Outcome of Board Meeting
Equirus Securities has organised an Earnings Conference Call on Tuesday, October 27, 2026 at 4.00 P.M. (IST) to discuss the financial results of the Company for the second quarter and half ....22 Oct 2026 · Company Update / Analyst / Investor Meet
Acutaas Chemicals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve Unaudited standalone & consolidated ....22 Oct 2026 · Board Meeting / Board Meeting
Completion of the Acquisition of the shares of the Step-down Subsidiary - Enchem Ami Organics Private Limited as per details attached.17 Oct 2026 · Company Update / Acquisition
Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2026 is attached.6 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 is enclosed.26 Sep 2026 · Company Update / Change in Management
Voting Results and Scrutinizers Report for the Annual General Meeting of the Company held on September 24, 2026 is attached.26 Sep 2026 · AGM/EGM / AGM
Board of Directors have approved the acquisition of equity shares of step down subsidiary company as per details enclosed.24 Sep 2026 · Company Update / Acquisition
Disclosure of events of the 19th Annual General Meeting held on Thursday, September 24, 2026 is attached.24 Sep 2026 · AGM/EGM / AGM
Intimation of Schedule of Investor Conference/Meet as per details attached.22 Sep 2026 · Company Update / Analyst / Investor Meet
Intimation of Closure of Trading Window is attached.22 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 is attached.10 Sep 2026 · Company Update / General
Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 in respect of inauguration of Pilot Plant today at Unit-1 Sachin is enclosed.4 Sep 2026 · Company Update / General
Newspaper publication for dispatch of notice of 19th AGM along with Annual Report for the FY 2025-26 is enclosed.31 Aug 2026 · Company Update / Newspaper Publication
Communication to shareholders issued in respect of deduction of TDS on Dividend , is herewith enclosed.29 Aug 2026 · Company Update / General
Intimation of Record date fixed for the purpose of Final Dividend for the FY 2025-26 is herewith enclosed.29 Aug 2026 · Corp. Action / Record Date
BRSR Report for the FY 2025-26 is herewith enclosed.29 Aug 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Annual Report for the FY 2025-26 is herewith enclosed.29 Aug 2026 · Others / Reg. 34 (1) Annual Report
Notice of the 19th Annual General Meeting of Company scheduled to be held on Thursday, September 24, 2026 at 11.30 A.M. IST is enclosed herewith.29 Aug 2026 · AGM/EGM / AGM
Press Release titled "Acutaas Chemicals'' step down subsidiary Indichem inaugurates Semiconductor Materials Plant at Gongju , The Republic of Korea", is attached.28 Aug 2026 · Company Update / Press Release / Media Release
Newspaper Publication in respect of 19th AGM of the company scheduled to be held on Thursday, September 24, 2026 is attached24 Aug 2026 · Company Update / Newspaper Publication
Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 is attached.22 Aug 2026 · Company Update / General
We wish to inform you that, Ministry of Electronics and Information Technology has accorded its approval for the incentive package under the ECMS scheme as per the details attached18 Aug 2026 · Company Update / General
Schedule of Investor Meet is attached.8 Aug 2026 · Company Update / Analyst / Investor Meet
Transcript of Earnings Call Q1 FY27 financial results held on July 24, 2026 is enclosed.28 Jul 2026 · Company Update / Earnings Call Transcript
Newspaper publication of Unaudited Financial Results of the Company for the quarter ended June 30, 2026 as per details attached.25 Jul 2026 · Company Update / Newspaper Publication
Recording of the Earnings Call held on July 24, 2026 is enclosed24 Jul 2026 · Company Update / General
Investor Presentation on financial results for the first quarter ended June 30, 2026 is attached.24 Jul 2026 · Company Update / Investor Presentation
Press Release discussing the financial results of first quarter ended as on June 30, 2026 is attached.24 Jul 2026 · Company Update / Press Release / Media Release
Unaudited Financial Results for the quarter ended June 30, 2026 is enclosed.24 Jul 2026 · Result / Financial Results
The Board of Directors of the Company at their meeting held on Friday, July 24, 2026, inter alia, considered & approved Unaudited Standalone & Consolidated Financial Results of the Company ....24 Jul 2026 · Board Meeting / Outcome of Board Meeting
Intimation of Earnings conference call scheduled on July 24, 2026 at 04.00 P.M. (IST)20 Jul 2026 · Company Update / Analyst / Investor Meet
Acutaas Chemicals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2026 ,inter alia, to consider and approve Unaudited standalone & consolidated ....20 Jul 2026 · Board Meeting / Board Meeting

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 2.5000	17 Sep 2026	17 Sep 2026	—
Final Dividend - Rs. - 1.5000	18 Sep 2025	18 Sep 2025	—
Stock Split From Rs.10/- to Rs.5/-	25 Apr 2025	25 Apr 2025	—
Final Dividend - Rs. - 3.0000	13 Sep 2024	13 Sep 2024	—

Board meetings

27 Oct 2026 Board Meeting - Financial Results
24 Jul 2026 Board Meeting - Financial Results